

# ForPatients

by Roche

Chronic Hepatitis B Hepatitis B Virus

## A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

**Trial Status**  
Completed

**Trial Runs In**  
13 Countries

**Trial Identifier**  
NCT04225715 2019-002086-35  
WV41073

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and without significant fibrosis/cirrhosis. The platform design allows comparison of multiple NME combination therapies against a common control, and introduction of additional treatment arms at later study time points. Each arm will consist of a screening phase (up to 8 weeks), treatment phase (up to 48 weeks) and post-treatment follow-up phase (48 weeks). The safety and efficacy will be monitored throughout the study.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT04225715 2019-002086-35 WV41073**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years & ≤ 65 Years

**Healthy Volunteers**  
No

---